PIK3CA mutations in cutaneous squamous cell carcinoma

• Published in: Intractable & Rare Diseases Research 2023/08/31, Vol.12(3), pp.206-207
• Main Authors: Kusaba, Yudo, Kajihara, Ikko, Sakamoto, Ryoko, Maeda-Otsuka, Saki, Yamada-Kanazawa, Saori, Sawamura, Soichiro, Makino, Katsunari, Aoi, Jun, Masuguchi, Shinichi, Fukushima, Satoshi
• Format: Article
• Language: English
• Subjects: cutaneous squamous cell carcinoma; Droplet digital polymerase chain reaction (ddPCR); Letter; metastasis; PIK3CA mutations
• ISSN: 2186-3644; 2186-361X
• DOI: 10.5582/irdr.2023.01069

Oncogenic PIK3CA mutation activates phosphoinositide 3-kinase (PI3K) enzyme, and PI3K-AKT signaling activation induces several growth-regulatory transcription factors. PIK3CA mutations have attracted attention as biomarker in clinical trials of various inhibitors including PI3K inhibitors. About 80% of PIK3CA mutations in human cancers are observed in 'hot spot' regions: exon 9 (E542K and E545K) and exon 20 (H1047R). There were few reports about clinical significance of PIK3CA mutations in cutaneous cell carcinoma (cSCC). Thus, we investigate the prevalence of three PIK3CA hot spot mutations in 143 cases with cSCC and evaluate the correlation between the presence of these mutations and clinical characteristics by using ddPCR. The frequency of each E542K, E545K and H1047R PIK3CA mutations was 1.4% (2/143), 2.8% (4/143), and 0.7% (1/143) respectively. No significant correlation was found between PIK3CA mutations and clinical characteristics. Although additional basic researches and clinical trials are necessary, various inhibitors may be effective therapeutics for PIK3CA mutation-positive cSCC. Our study revealed the prevalence of PIK3CA mutations in cSCC.